Inactive Instrument

Voluntis S.A. Stock price

Equities

ALVTX

FR0004183960

Software

Dynamic Chart
AptarGroup, Inc. completed the acquisition of remaining 35.4% stake in Voluntis S.A.. CI
Global markets live: Intel, Apple, Rolls-Royce, Raytheon, MGM... Our Logo
Global markets live: Thales, Nestlé, Evergrande, AMC, Walmart... Our Logo
Global markets live: Amazon, Delivery Hero, Walmart, Broadcom, JD.com, Didi Global... Our Logo
AptarGroup : Completes Deal to Buy Nearly 65% of Voluntis; Mandatory Takeover Offer to Commence MT
AptarGroup : Completes Acquisition of Majority Stake in Voluntis MT
Voluntis S.A. Announces Executive Changes CI
AptarGroup, Inc. made an offer to acquire remaining 35.4% stake in Voluntis S.A. for €27.4 million. CI
AptarGroup, Inc. completed the acquisition of 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel. CI
AptarGroup : Signs Deal to Buy Majority Stake in Digital Therapeutics Firm Voluntis for 8.70 Euros Per Share MT
AptarGroup, Inc. signed a share purchase agreement to acquire 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel for €50.1 million. CI
Linklaters Advises Aptar on Entering into Exclusive Negotiations Regarding A Potential Acquisition of Voluntis CI
Voluntis Enters into Exclusive Negotiations with AptarGroup CI
AptarGroup : Says in Exclusive Negotiations on Potential Acquisition of Voluntis MT
Global markets live: Apple, Nvidia, Biogen, Fastly, Tilray... Our Logo
More news
Managers TitleAgeSince
Founder 45 00-12-31
Founder - 00-12-31
Founder 46 00-12-31
Members of the board TitleAgeSince
Director/Board Member 64 -
Founder 46 00-12-31
Director/Board Member 67 18-10-24
More insiders
Voluntis SA is a France-based company specialized in medical solutions. The Company designs prescription applications that embed medical intelligence in the smart phones of people suffering from chronic and rare diseases. Voluntis SA develops digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Its product portfolio includes Insulia, a prescription-only medical device, which is a digital therapeutic for people with type 2 diabetes who are being treated with long-acting basal insulin. The medical device also provides patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; Theraxium platform, which is a flexible platform that transforms health data into medical intelligence, and Quality and Regulatory Expertise, which focuses on patient safety, among others.
More about the company
1st Jan change Capi.
-15.42% 226B
-1.20% 72.01B
+2.87% 60.02B
+6.96% 55.71B
+1.83% 41.02B
-3.03% 35.47B
-4.33% 30.21B
+73.70% 22.8B
+7.99% 22.59B
Application Software
  1. Stock
  2. Equities
  3. Stock Voluntis S.A. - Euronext Paris